293 related articles for article (PubMed ID: 20664052)
1. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.
Noonan K; Marchionni L; Anderson J; Pardoll D; Roodman GD; Borrello I
Blood; 2010 Nov; 116(18):3554-63. PubMed ID: 20664052
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.
Noonan KA; Huff CA; Davis J; Lemas MV; Fiorino S; Bitzan J; Ferguson A; Emerling A; Luznik L; Matsui W; Powell J; Fuchs E; Rosner GL; Epstein C; Rudraraju L; Ambinder RF; Jones RJ; Pardoll D; Borrello I
Sci Transl Med; 2015 May; 7(288):288ra78. PubMed ID: 25995224
[TBL] [Abstract][Full Text] [Related]
3. RORC overexpression as a sign of Th17 lymphocytes accumulation in multiple myeloma bone marrow.
Ben Hmid A; Selmi O; Rekik R; Lamari H; Zamali I; Ladeb S; Safra I; Ben Othman T; Ben Romdhane N; Ben Ahmed M
Cytokine; 2020 Oct; 134():155210. PubMed ID: 32707421
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.
Dhodapkar KM; Barbuto S; Matthews P; Kukreja A; Mazumder A; Vesole D; Jagannath S; Dhodapkar MV
Blood; 2008 Oct; 112(7):2878-85. PubMed ID: 18669891
[TBL] [Abstract][Full Text] [Related]
5. Development of an in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast function in Paget's disease and multiple myeloma.
Roodman GD
Bone; 1995 Aug; 17(2 Suppl):57S-61S. PubMed ID: 8579899
[TBL] [Abstract][Full Text] [Related]
7. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells.
Uchida A; Yagita M; Sugiyama H; Hoshino T; Moore M
Int J Cancer; 1984 Sep; 34(3):375-81. PubMed ID: 6592156
[TBL] [Abstract][Full Text] [Related]
8. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
9. Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.
Cui Q; Shibata H; Oda A; Amou H; Nakano A; Yata K; Hiasa M; Watanabe K; Nakamura S; Miki H; Harada T; Fujii S; Kagawa K; Takeuchi K; Ozaki S; Matsumoto T; Abe M
Int J Hematol; 2011 Jul; 94(1):63-70. PubMed ID: 21698356
[TBL] [Abstract][Full Text] [Related]
10. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Hecht M; von Metzler I; Sack K; Kaiser M; Sezer O
Exp Cell Res; 2008 Mar; 314(5):1082-93. PubMed ID: 18053985
[TBL] [Abstract][Full Text] [Related]
11. 'Role of bone marrow stromal cells in the growth of human multiple myeloma.
Caligaris-Cappio F; Bergui L; Gregoretti MG; Gaidano G; Gaboli M; Schena M; Zallone AZ; Marchisio PC
Blood; 1991 Jun; 77(12):2688-93. PubMed ID: 1675130
[TBL] [Abstract][Full Text] [Related]
12. miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma.
Rossi M; Altomare E; Botta C; Gallo Cantafio ME; Sarvide S; Caracciolo D; Riillo C; Gaspari M; Taverna D; Conforti F; Critelli P; Bertucci B; Iannone M; Polerà N; Scumaci D; Arbitrio M; Amodio N; Di Martino MT; Paiva B; Tagliaferri P; Tassone P
Leukemia; 2021 Mar; 35(3):823-834. PubMed ID: 32632096
[TBL] [Abstract][Full Text] [Related]
13. Cellular mechanisms of multiple myeloma bone disease.
Oranger A; Carbone C; Izzo M; Grano M
Clin Dev Immunol; 2013; 2013():289458. PubMed ID: 23818912
[TBL] [Abstract][Full Text] [Related]
14. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
Prabhala RH; Pelluru D; Fulciniti M; Prabhala HK; Nanjappa P; Song W; Pai C; Amin S; Tai YT; Richardson PG; Ghobrial IM; Treon SP; Daley JF; Anderson KC; Kutok JL; Munshi NC
Blood; 2010 Jul; 115(26):5385-92. PubMed ID: 20395418
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of myeloma-induced bone disease].
Abe M
Clin Calcium; 2016 May; 26(5):699-706. PubMed ID: 27117615
[TBL] [Abstract][Full Text] [Related]
16. The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.
Foglietta M; Castella B; Mariani S; Coscia M; Godio L; Ferracini R; Ruggeri M; Muccio V; Omedé P; Palumbo A; Boccadoro M; Massaia M
Haematologica; 2014 Oct; 99(10):1605-10. PubMed ID: 24972771
[TBL] [Abstract][Full Text] [Related]
17. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
18. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.
Choi SJ; Cruz JC; Craig F; Chung H; Devlin RD; Roodman GD; Alsina M
Blood; 2000 Jul; 96(2):671-5. PubMed ID: 10887133
[TBL] [Abstract][Full Text] [Related]
19. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.
Calcinotto A; Brevi A; Chesi M; Ferrarese R; Garcia Perez L; Grioni M; Kumar S; Garbitt VM; Sharik ME; Henderson KJ; Tonon G; Tomura M; Miwa Y; Esplugues E; Flavell RA; Huber S; Canducci F; Rajkumar VS; Bergsagel PL; Bellone M
Nat Commun; 2018 Dec; 9(1):4832. PubMed ID: 30510245
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the role of Tregs in the progression of multiple myeloma.
Lad D; Huang Q; Hoeppli R; Garcia R; Xu L; Levings M; Song K; Broady R
Leuk Lymphoma; 2019 Sep; 60(9):2134-2142. PubMed ID: 30773086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
